The recent activity involving Cadrenal Therapeutics' CEO and Chairman, Pham Quang X, includes the sale of common stock shares across two transactions in late May and early June. These sales totaled $3,074, with the executed prices ranging between $4.46 and $5.01 per share.
According to filings detailing these dispositions, Mr. Pham first sold 303 shares of common stock on May 29, 2026. This initial batch was transacted at a weighted average price of $5.01, with individual sale prices observed between $5.00 and $5.02 per share.
A second set of sales followed shortly after, on June 2, 2026. On this occasion, Mr. Pham disposed of an additional 349 shares of Cadrenal Therapeutics common stock. These shares were sold at a weighted average price of $4.46, with prices for individual transactions recorded between $4.40 and $4.62.
It is important to note that both sets of insider sales were executed under the framework of a Rule 10b5-1 trading arrangement. This plan had been adopted by Mr. Pham previously on September 25, 2025.
These reported insider sales are occurring as Cadrenal Therapeutics' stock trades near its 52-week low of $4.14, with the current share price noted at $4.35. Analysis from InvestingPro suggests that the company may be undervalued at present levels, citing a market capitalization of $14.5 million.
Following these transactions, Mr. Pham's direct holdings in Cadrenal Therapeutics common stock amount to 181,509 shares. Furthermore, his indirect stake is managed through The PVBQ Living Trust. In this trust, he serves as the Trustee and maintains sole voting and dispositive power, representing an additional holding of 200,000 shares. The beneficiary designated for this trust is his child.
Beyond the trading activity, Cadrenal Therapeutics Inc. has reported significant operational updates. For the fourth quarter ending December 31, 2025, the company recorded a net loss of $3.0 million. This figure represents an improvement compared to the $4.2 million loss incurred during the same period in the previous year.
A major development involves the completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). During this interaction, the company received explicit guidance to advance its investigational treatment, CAD-1005, for treating heparin-induced thrombocytopenia toward a pivotal Phase 3 clinical trial.
This planned Phase 3 study is structured as a randomized, blinded, placebo-controlled investigation anticipated to involve approximately 120 patients globally. Cadrenal plans to fully integrate the FDA's feedback into the design of this pivotal trial. The guidance covers several critical areas, including protocol design, the specific patient population, appropriate dosing regimens, background therapy considerations, exposure parameters, safety database requirements, and primary endpoints.
Specifically, the primary endpoint for the Phase 3 trial will focus on new or worsening thrombotic events. Looking ahead, the company is aiming for this comprehensive trial to support a projected New Drug Application (NDA) submission in 2029. These combined developments underscore Cadrenal's ongoing progress in advancing its drug pipeline while simultaneously managing its financial reporting.
Risks
- The stock trades near its 52-week low of $4.14, indicating significant market pressure despite positive pipeline news.
- The company reports a net loss for the fourth quarter ending December 31, 2025 ($3.0 million), which represents ongoing financial expenditure.
- Future success relies on successfully completing and executing the randomized, blinded, placebo-controlled Phase 3 trial, with primary endpoints focused on new or worsening thrombotic events.
More from Insider Trading